Randomized study with oral tegafur versus capecitabina in the treatment of advanced politreated breast cancer and refractory, resistant or in progression to the standard chemotherapeutic treatment

INTERVENTION: Trade Name: UTEFOS cápsulas Product Name: Tegafur Pharmaceutical Form: Coated tablet INN or Proposed INN: tegafur Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400‐ CONDITION: breast cancer ; Classification code 10027475 PRIMARY OUTCOME: Main Objective: To compare the effectiveness of oral Tegafur versus oral capecitabina in affected patients of metastatic breast cancer treated previously with several lines of chemotherapy in terms of time to the progression; Primary end point(s): Time to the progression: defined as the time passed from the inclusion of the patient in the study to date in which tumorlike progression is demonstrated; Secondary Objective: Rate of objective response ; Study of the toxicity of both schemes of treatment; Evaluation of the Quality of Life ; Global Survival ; Study of costs ; Study of cumplimentation preference; INCLUSION CRITERIA: ‐ Patients with diagnosis of metastatic breast cancer in progression or stabilization, after receiving 2‐3 lines of chemotherapy, in the following situations: ‐ breast cancer, refractory or resistant to the standard treatments ‐ breast cancer in progression that has received different lines of previous chemotherapy with antraciclins or taxans and is not had effective alternative treatment ‐ Like treatment of maintenance and/or palliative in politreated patients, with advanced breast cancer and that are stabilized with active disease ‐ Age : = 18 a. ‐ Karnofski >50% / Performance status ECOG = 2 ‐ Expectance Life > 12 semanas ‐ Suitable functions: bone marrow, renal and hepatic ‐ Vomit, diarrhea and mucositis absence. Previous pathology cardiac absence ‐ Existence of evaluables and/or measurable parameters ‐ Not to have received treatment of chemotherapy within the 3‐4 previous weeks at the beginning of treatment ‐ Signed infor